WALTHAM, Mass., Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostictests, today announced that it has reached a settlement with the United States Securities and Exchange Commission (the "SEC") in connection with the SEC's previously disclosed investigation. The SEC investigation primarily involved certain accounting
Alere issued the following statement:
We have cooperated with the SEC and we are pleased to fully resolve this matter.
Under the terms of the settlement, Alere agreed to pay approximately $13 million to the SEC and consented to the entry by the SEC of an administrative cease-and-desist order, issued today by the SEC, without admitting or denying the findings in the order.
About Alere Alere believes that when diagnosing and monitoring health conditions, Knowing now matters. Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visit www.alere.com.
View original content:http://www.prnewswire.com/news-releases/alere-announces-settlement-with-sec-300527648.html
SOURCE Alere Inc.
Subscribe to our Free Newsletters!
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...View All